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Background: Few studies have examined the effects of on-treatment platelet reactivity on the risk of major ad-
verse cardiovascular events (MACE). We aimed to determine the optimal cutoff value of P2Y12 reaction units
(PRUs) to prevent MACE occurring within 3 days after percutaneous coronary intervention (PCI) for acute coro-
nary syndrome (ACS).
Methods:Weperformedpost-hoc analyses of 1363 patients enrolled in PRASFIT-ACS,which compared the effects
of a prasugrel regimen adjusted for Japanese patients (loading dose/maintenance dose: 20 mg/3.75 mg) with
those of clopidogrel (300 mg/75 mg) on MACE and bleeding events for 24–48 weeks after PCI in ACS patients.
PRU was serially measured using the VerifyNow® P2Y12 assay and we assessed the relationship between PRU
and MACE.
Results: Receiver operating characteristic curve analysis showed that PRU≤262 at 5–12 h after ADP receptor an-
tagonist loading was the optimal cutoff value for preventing MACE at up to 3 days after PCI. The incidences of
MACE were 5.2% and 10.8% in patients with PRU≤262 or N262, respectively (odds ratio 0.50, 95% conﬁdence in-
terval 0.25–0.99, p b 0.01). Signiﬁcantlymoreprasugrel-treatedpatients had lower on-treatment platelet reactiv-
ity (deﬁned as PRU ≤262) compared with clopidogrel-treated patients (79.9% vs. 30.4%, p b 0.0001). Similar
differences were observed between the prasugrel and clopidogrel groups for patients with normal or reduced-
function CYP2C19 alleles.
Conclusions: The optimal PRU cutoff value for preventing MACE was 262 in Japanese ACS patients. Prasugrel rap-
idly reduced PRU with a large proportion of patients having low on-treatment platelet reactivity.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).rel For Japanese patIenTs with
ronary intervention (JapicCTI-
n Pharmaceutical Information
ls.jp/user/cteSearch.jsp).
i Medical Center, Division of
53-8515, Japan.
ura).
land Ltd. This is an open access articl1. Introduction
Dual antiplatelet treatment with aspirin and clopidogrel is widely
recommended as a treatment for acute coronary syndrome [1,2]. How-
ever, clopidogrel shows a delayed onset of action and its pharmacody-
namic effect may be insufﬁcient to adequately suppress platelet
aggregation to prevent thrombotic events [3]. Furthermore, clopidogrel
exhibits pharmacodynamic variability between individuals, mainly be-
cause of genetic variations in cytochrome P450 (CYP) 2C19 [4–6].
Therefore, some clopidogrel-treated patients exhibit high on-e under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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risk of ischemic events such as stent thrombosis [7–10]. Thus, newer
P2Y12 receptor antagonistswithmore potent and quicker pharmacolog-
ical effects have been developed. These newer agents, namely prasugrel
and ticagrelor, showed superiority over clopidogrel in clinical trials [11,
12], although the stronger antiplatelet effects of prasugrel and ticagrelor
were associatedwith a greater risk of non-coronary artery bypass graft-
related major bleeding, partly offsetting the clinical beneﬁts of these
drugs in both trials.
A concern about prasugrel has arisen in that the lower body weight
of Japanese populationsmay increase their bleeding risk relative to that
in Western populations. Therefore, we examined the clinical efﬁcacy of
a prasugrel regimen optimized for Japanese patients (loading dose [LD]/
maintenance dose [MD]: 20 mg/3.75 mg) used in an earlier Japanese
phase II trial (unpublished data). This dose was selected based on the
results of a phase I study using LD/MD of 10/2.5 mg, 15/3.75 mg, and
20/5 mg [13]. This regimen was associated with a low incidence of
major adverse cardiac events (MACE) without an increased risk of clin-
ically serious bleeding in JapaneseACS patients enrolled in amulticenter
randomized controlled study (PRASFIT-ACS: PRASugrel compared with
clopidogrel For Japanese patIenTs with Acute Coronary Syndrome un-
dergoing percutaneous coronary intervention) [14]. The incidence of
MACE within 3 days after percutaneous coronary intervention (PCI) in
PRASFIT-ACS was 5.3% in the prasugrel group and 8.3% in the
clopidogrel group (hazard ratio [HR] 0.63, 95% conﬁdence interval [CI]
0.41–0.95, p = 0.026; full analysis set: 1363 patients).
It was postulated that the point of care approach for ACS patients
might help to reduce both ischemic and bleeding events, as studies
assessing the potential cutoff value for platelet inhibition observed out-
comes that tended to be inconsistent among prior studies [15–17]. In
addition, observational studies demonstrated a relationship between
adverse events and HPR [15]. The results of randomized trials that in-
vestigated the value of a personalized antiplatelet treatment regimen
based on platelet function did not support the point of care approach
[16,17]. These inconsistencies may be explained by the fact that the pa-
tients enrolled in randomized controlled studies were generally limited
to patients with stable coronary artery disease undergoing elective PCI.
In trials addressing the efﬁcacy of different antiplatelet regimens for
ACS patients, a division in the Kaplan–Meier curves of cumulativeMACE
was observed immediately after randomization and the curves contin-
ued to separate over time, which suggests that more potent antiplatelet
therapies confer ongoing beneﬁts on MACE [11,12,14]. This ﬁnding
demonstrates the efﬁcacy of potent and rapidly acting antiplateletFig. 1. Time-course of platelet reactivity determined by theVerifyNow® P2Y12 assay after the lo
measures ANOVA; the least square mean in themodel was compared among groups at each tim
loading dose; MD: maintenance dose; PRU: platelet reactivity unit.regimens. However, the relationship between MACE and platelet func-
tion inhibition, in terms of P2Y12 reaction units (PRUs), during the
acute phase after the LD has not been comprehensively assessed. There-
fore, we conducted a post-hoc analysis of the results of the PRASFIT-ACS
study to investigate the association between platelet reactivity in the
acute, early phase after the LD and adverse cardiac events occurring
up to 3 days after PCI in Japanese ACS patients. We chose the acute pe-
riod of treatment (up to 3 days after PCI) because themajority of cardio-
vascular events occurred in this period and because of the ease of
monitoring the platelet inhibition using point-of-care assays.
2. Methods
2.1. Study design
PRASFIT-ACSwas amulticenter, randomized, double-blind, double-dummy, two-way
parallel-group study performed at 162 sites in Japan between December 2010 and June
2012 (Appendix A) [14]. The database was locked on September 2012. The patients
were treated for 24–48weekswith the allocated study drug, afterwhich theywere follow-
ed up for a further 14 days to detect possible safety issues or other events occurring after
completing treatment. Eligible patients were randomized (1:1) to either prasugrel or
clopidogrel after providing written informed consent. The LD of prasugrel (20 mg) or
clopidogrel (300 mg) was usually administered before PCI, but could be administered
up to 1 h after the patient left the cardiac catheter laboratory in urgent cases (urgent
cases: 29.2%). After PCI, the patients received theMDof prasugrel (3.75mg) or clopidogrel
(75 mg) once daily after breakfast during the treatment period. Treatment was intended
to continue for 48 weeks, but could be completed at 24 weeks if the investigator deemed
it appropriate for the individual patient, taking into account the stent type and the recom-
mended duration of thienopyridine administration, as stated in the package inserts. The
concomitant use of antiplatelet drugs (other than aspirin), anticoagulant drugs, thrombo-
lytic drugs, or acidic non-steroidal anti-inﬂammatory drugs was prohibited. The CYP2C19
genotypewas assessed as described below. The studywas conducted in accordancewith the
Declaration ofHelsinki in compliancewithGoodClinical Practice. The studywas approved by
the institutional review boards at all of the participating institutions. PRASFIT-ACSwas regis-
tered on the Japan Pharmaceutical Information Center Clinical Trials Information database
(http://www.clinicaltrials.jp/user/cteSearch.jsp) with the identiﬁer JapicCTI-101339.
2.2. Patients
The enrollment process and eligibility criteria are reported in more detail elsewhere
[14]. In brief, patients were eligible if they satisﬁed all of the following criteria: presenting
with chest discomfort or ischemic symptoms lasting≥10minwithin 72 h before random-
ization, myocardial ischemia (conﬁrmed by electrocardiography), or myocardial necrosis
(conﬁrmed by changes in cardiac biomarkers). Patients with a history of intracranial
bleeding or ischemic stroke/transient ischemic attack, current or predisposition to hemor-
rhagic disease, or poorly controlled hypertension were excluded. Platelet reactivity data
were obtained in 1256/1363 patients enrolled in PRASFIT-ACS. Of these patients, platelet
function was measured 5–12 h after the LD (mean: 7 h 29 min; median: 6 h 54 min) in
660 patients. These patients were included in analyses of platelet inhibition and MACE
in this post-hoc analysis.ading dose and during themaintenance dose phase. *p b 0.0001 vs. clopidogrel by repeated
e point, and time points showing a signiﬁcant difference are markedwith an asterisk. LD:
Table 1
Characteristics of patients in whom platelet reactivity was assessed at 5–12 h after the
loading dose.
Prasugrel
(n = 328)
Clopidogrel
(n = 332)
All patients
(n = 660)
χ2 test
(*t-Test)
Females 60 (18.3) 67 (20.2) 127 (19.2) 0.5384
Age, years 65.2 ± 11.7 65.6 ± 11.3 65.4 ± 11.5 0.6461*
≥75 years 78 (23.8) 81 (24.4) 159 (24.1) 0.8529
Body weight, kg 64.8 ± 12.2 64.4 ± 11.4 64.6 ± 11.8 0.6035*
≤50 kg 34 (10.4) 42 (12.7) 76 (11.5) 0.3579
≤60 kg 120 (36.6) 119 (35.8) 239 (36.2) 0.8428
BMI, kg/m2 24.2 ± 3.4 24.4 ± 3.3 24.3 ± 3.4 0.5688*
Current smoker, yes 136 (41.5) 130 (39.2) 266 (40.3) 0.0774
Cardiac conditions 0.0143
UA 70 (21.3) 44 (13.3) 114 (17.3)
NSTEMI 81 (24.7) 107 (32.2) 188 (28.5)
STEMI 176 (53.7) 181 (54.5) 357 (54.1)
CrCL (ml/min) 0.9965
Eligible, n 298 302 600
≥60 ml/min 236 (79.2) 240 (79.5) 476 (79.3)
b60 ml/min 62 (20.8) 62 (20.5) 124 (20.7)
Clinically relevant disorders
Hypertension 238 (72.6) 251 (75.6) 489 (74.1) 0.3726
Dyslipidemia 255 (77.7) 250 (75.3) 505 (76.5) 0.4592
Diabetes mellitus 129 (39.3) 116 (34.9) 245 (37.1) 0.2432
Concomitant therapy
Proton pump inhibitor 145 (44.2) 149 (44.9) 294 (44.5) 0.8621
Statin 175 (53.4) 161 (48.5) 336 (50.9) 0.2118
Ca channel blocker 86 (26.2) 70 (21.1) 156 (23.6) 0.1205
ACEI 66 (20.1) 42 (12.7) 108 (16.4) 0.0095
ARB 92 (28.0) 86 (25.9) 178 (27.0) 0.5347
β-Blocker 63 (19.2) 45 (13.6) 108 (16.4) 0.0497
First revascularization 0.9759
PCI 324 (98.8) 330 (99.4) 654 (99.1)
CABG 2 (0.6) 1 (0.3) 3 (0.5)
None 3 (0.9) 1 (0.3) 4 (0.6)
Treatment vessel 0.5656
Single 221 (67.4) 233 (70.2) 454 (68.8)
Multiple 103 (31.4) 97 (29.2) 200 (30.3)
No PCI 4 (1.2) 2 (0.6) 6 (0.9)
Type of stent 0.5754
BMS 171 (53.3) 180 (55.4) 351 (54.3)
DES 152 (47.4) 147 (45.2) 299 (46.3)
Timing of LD 0.6943
Before PCI 196 (59.7) 202 (60.8) 398 (60.3)
During PCI 19 (5.8) 26 (7.8) 45 (6.8)
After PCI 109 (33.2) 102 (30.7) 211 (32.0)
No PCI 4 (1.2) 2 (0.6) 6 (0.9)
CYP2C19 phenotype 0.9252
Eligible, n 220 211 431
Normal function (EM) 87 (39.5) 80 (37.9) 167 (38.7)
Reduced function 133 (60.5) 131 (62.1) 264 (61.3)
IM 92 (41.8) 92 (43.6) 184 (42.7)
PM 41 (18.6) 39 (19.5) 80 (18.6)
Values are means ± standard deviation or n (%).
BMI: bodymass index; UA: unstable angina; NSTEMI: non-ST-elevationmyocardial infarc-
tion; STEMI: ST-elevation myocardial infarction; CrCL: creatinine clearance (estimated
using the Cockcroft–Gault formula); Ca: calcium; ACEI: angiotensin-converting enzyme
inhibitor; ARB: angiotensin receptor blocker; PCI: percutaneous coronary intervention;
CABG: coronary artery bypass graft; BMS: bare metal stent; DES: drug-eluting stent; LD:
loading dose; EM: extensive metabolizers; IM: intermediate metabolizers; PM: poor
metabolizers.
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The primary efﬁcacy endpoint (i.e., MACE) was a composite of cardiovascular death,
non-fatal myocardial infarction, and non-fatal ischemic stroke. Non-fatal myocardial in-
farction was deﬁned as events fulﬁlling at least one of the following three criteria. First,
in patients with normal creatine kinase-MB before PCI/coronary artery bypass grafting,
creatine kinase-MB had to be greater than (a) three times the upper limit of normal in
two samples obtained after PCI, or greater than ﬁve times the upper limit of normal in
one sample obtained b48 h after PCI/coronary artery bypass grafting, or (b) 10 times the
upper limit of normal in one sample obtained b48 h after coronary artery bypass grafting.
Creatine kinase-MB before PCI/coronary artery bypass grafting had to show a transient de-
creasewith re-elevation at least 1.5 times the upper limit of normal, and also satisfy (a) or
(b). Second, 48 h after PCI, creatine kinase-MB or troponin had to be greater than the
upper limit of normal, and accompanied by one of the following: c) sustained ischemic
chest pain, d) hemodynamic decompensation, or e) ST elevation or depression of
≥0.1 mV. Third, abnormal Qwaves had to persist for N0.04 s. The other efﬁcacy endpoints
were assessed by calculating the incidence of cardiovascular deaths, all-cause death, non-
fatal myocardial infarction, non-fatal stroke with/without ischemia, myocardial ischemia
requiring rehospitalization, revascularization, and stent thrombosis deﬁned as deﬁnite
or probable according to Academic Research Consortium criteria [18].
2.4. Platelet aggregation study
The pharmacodynamics of prasugrel and clopidogrel were assessed using the
VerifyNow® P2Y12 assay (Accumetrics, San Diego, California) in patients who permitted
blood collection. VerifyNow® P2Y12 baseline reactivity, PRU, and percent inhibition of
P2Y12 were assessed. PRU was measured at baseline, in the LD phase (2–4, and 5–12 h
after the LD), and during the MD phase (at 4, 12, 24, 36, and 48 weeks after PCI).
Whole-blood samples (approximately 2 ml) were collected from non-fasted patients in
tubes containing 3.2% sodium citrate. The blood samples were left for 10min up to 4 h be-
fore measurement. Whole-blood samples were used and measurements were performed
according to the manufacturer's instructions.
2.5. Assessment of the CYP2C19 genotype
The genotypes of the CYP2C19*2 and *3 alleles, which markedly decrease CYP2C19
enzyme activity, were determined using the TaqMan™ Drug Metabolism Genotyping As-
says in 220 prasugrel-treated patients and 211 clopidogrel-treated patients who gave in-
formed consent for these tests. The genotypes were classiﬁed into three phenotypes:
extensive metabolizers (EM) with normal function alleles (CYP2C19*1/*1), intermediate
metabolizers (IM) with one reduced-function allele (*1/*2, *1/*3), and poor metabolizers
(PM) with two reduced-function alleles (*2/*2, *2/*3, *3/*3).
2.6. Statistical methods
For subject background characteristics, we compared categorical outcomes using the
χ2 or Fisher's exact tests and continuous variables using the Student's t test. Differences be-
tween groups in terms of the time-course of platelet reactivity and the effects of CYP2C19
alleles on platelet reactivitywere determined by repeatedmeasures ANOVAwith compar-
ison of the least square means. The proportions of patients with platelet reactivity units
below the cutoff value were compared using the χ2 test. Results are presented as means
(standard deviation). Receiver operating characteristic analyses were conducted to deter-
mine theusefulness of PRU for distinguishingbetweenpatientswith andwithout ischemic
cardiovascular events in theperiprocedural period (i.e., up to 3 days after PCI). The optimal
cutoff value was the on-treatment PRU that provided the greatest sum of sensitivity and
speciﬁcity. After applying the proportional hazard assumption, the Cox regression model
was used for univariate and multivariate analyses to identify risk factors for MACE occur-
ringwithin 3 days after PCI, and to adjust for potential confounders associatedwithMACE
(multivessel lesions, hypertension, dyslipidemia, current smoker, prior myocardial infarc-
tion, and treatment received). All statistical analyses were performed using SAS version
9.2 (SAS Institute, Cary, North Carolina).
3. Results
3.1. PRU after administration of prasugrel or clopidogrel in the overall study
population
As shown in Fig. 1, PRUmeasured using the VerifyNow®P2Y12 assay
at 2–4 h (p b 0.0001) and 5–12 h (p b 0.0001) after the LD was signiﬁ-
cantly lower in the prasugrel group than in the clopidogrel group. This
effect of prasugrel persisted into the MD treatment period at 4, 12, 24,
36, and 48 weeks (all, p b 0.0001). The LD of clopidogrel did not reduce
PRU at up to 12 h after administration, but 4 weeks of treatment with
the MD did reduce PRU. However, the reduction in PRU after 4 weeks
of treatment was smaller in the clopidogrel group than in the prasugrel
group.3.2. Characteristics of patients included in the analyses of PRU to avoid
MACE
Table 1 shows the characteristics of 660 patients (prasugrel, 328;
clopidogrel, 332) in whom PRU was measured at 5–12 h after the LD.
There were some differences in the clinical presentation (prevalences
of unstable angina and non-ST-elevation myocardial infarction) be-
tween the two treatment groups, but other characteristics were similar
in both groups.
Overall, 51/660 patients (7.7%) experienced MACE. The incidence of
MACE was 6.1% (20/328) in the prasugrel group and 9.3% (31/332) in
Fig. 3. Receiver operating characteristic curve for platelet reactivity units determined
using the VerifyNow® P2Y12 assay. AUC: area under the curve; CI: conﬁdence interval.
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0.34–1.12).
3.3. Association between platelet reactivity and MACE
Weplotted the PRUmeasured at 5–12h after the LD according to the
study drug received (Fig. 2A), and in all patients with or without MACE
(Fig. 2B). PRU valueswere higher in patientswithMACE than in patients
withoutMACE (Fig. 2B). Receiver operating characteristic curve analysis
was performed using PRU for on-treatment platelet reactivity in all pa-
tients to distinguish between patients with or without MACE (Fig. 3).
The area under the curve was 0.58 (95% CI 0.50–0.65) and PRU of 262
was the optimal cutoff value for preventing MACE after PCI. The overall
incidence of MACE through to day 3 was 5.2% (19/363) in patients with
PRU ≤262 and 10.8% in patients with PRU N262 (risk reduction 0.5, OR
0.50, 95% CI: 0.25–0.99, p b 0.01) (Table 2; Fig. 4, inset). The values at
week 24 in patients with PRU ≤262 and patients with PRU N262 were
8.8% (32/328) and 15.5% (46/297), respectively, corresponding to
a risk reduction of 49% (OR 0.51, 95% CI 0.29–0.90) (Fig. 4). PRU
was ≤262 in signiﬁcantly more prasugrel-treated patients than
clopidogrel-treated patients (79.9% vs. 30.4%, p b 0.0001; Fig. 5). How-
ever, the ORs for MACE in patients with PRU ≤262 vs. PRU N262 were
similar in both groups (Table 2). In multivariate Cox regression analysis
(Table 3), PRU N262 was independently associated with a higher risk of
MACE (HR 2.02, 95% CI 1.05–3.90, p b 0.05) after adjusting for confound-
ing factors that were associated with MACE in univariate analyses. In
this analysis, the presence of multivessel disease was also a signiﬁcant
risk factor for MACE (p b 0.05).
3.4. Effects of CYP2C19 polymorphisms on changes in PRU and the propor-
tions of patients with PRU ≤262
Only 18.6% of patientswith knownCYP2C19 statuswere classiﬁed as
PM (Table 1). Therefore, we combined the PM and IM groups to provide
a larger group of patients with reduced-function CYP2C19 polymor-
phisms. This allowed us to increase the reliability of statistical analyses
by comparing patients with normal or reduced-function CYP2C19 poly-
morphisms. The proportion of patientswith PRU≤262was signiﬁcantly
higher in theprasugrel group than in the clopidogrel group (pb 0.0001).
Similar differences were observed between the prasugrel and
clopidogrel groups for patients with normal (85.1% vs. 45.0%, p b
0.0001) or reduced-function (76.7% vs. 27.5%, p b 0.0001) CYP2C19
alleles. In the clopidogrel group, the proportion of patients with
PRU ≤262 was signiﬁcantly (p b 0.01) smaller among patients with
reduced-function alleles than among patients with normal function al-
leles (Fig. 6). The reduction in PRU in the acute phase after PCI wasFig. 2. Platelet reactivity determined by the VerifyNow® P2Y12 assay at 5–12 h after administra
tients with or without major adverse cardiovascular events within 3 days after percutaneous c
unit.signiﬁcantly greater in the prasugrel group than in the clopidogrel
group irrespective of CYP2C19 status (p b 0.0001) (Fig. 7). The prasugrel
MD achieved signiﬁcantly greater reductions in PRU than did the
clopidogrel MD among patients with reduced-function CYP2C19 alleles.
4. Discussion
This post-hoc analysis of the PRASFIT-ACS study had three main
ﬁndings. 1) Platelet reactivity at 5–12 h after the LD of clopidogrel or
prasugrel was associated with MACE up to 3 days after PCI in ACS pa-
tients. 2) PRU≤262was a clinically relevant cutoff value for preventing
MACE after PCI and the proportion of non-responders (PRU N262) was
signiﬁcantly lower in the prasugrel group than in the clopidogrel group
(20.1% vs. 69.6%, p b 0.0001). 3) Prasugrel was associated with a higher
achievement rate of PRU ≤262 compared with clopidogrel in patients
with normal or reduced-function CYP2C19 alleles.
4.1. Association between platelet reactivity and adverse events
Numerous reports have described an association between platelet
reactivity and ischemic events. For example, Marcucci et al. [15]tion of the loading dose. (A) All patients treated with prasugrel or clopidogrel. (B) All pa-
oronary intervention. MACE: major adverse cardiovascular events; PRU: platelet reactivity
Table 2
Incidence of major adverse cardiovascular events in patients divided by platelet reactivity.
Number of
patients
Patients with
MACEa
Prasugrel Clopidogrel
All patients 660 51 (7.7%) 328 332
PRU N262b 297 32 (10.8%) 6/66 (9.1%) 26/231 (11.3%)
CV deathc 2/297 (0.7%) 0/66 (0%) 2/231 (0.9%)
MIc 30/297 (10.1%) 6/66 (9.1%) 24/231 (10.4%)
PRU ≤262b 363 19 (5.2%) 14/262 (5.3%) 5/101 (5.0%)
MIc 19/363 (5.2%) 14/262 (5.3%) 5/101 (5.0%)
OR 0.497 0.559 0.445
95% CI 0.249–0.989 0.205–1.523 0.163–1.218
p value b0.01 0.232 0.085
CI: conﬁdence interval; MACE: major adverse cardiovascular events; MI: myocardial infarction; PRU: platelet reactivity unit; OR: odds ratio; CV: cardiovascular death.
a MACE occurring within 3 days after percutaneous coronary intervention.
b PRU at 5–12 h after treatment was determined using the VerifyNow® P2Y12 assay.
c n (%) of patients whose event was classiﬁed as MI or CV death.
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clopidogrel was associated with the incidence of ischemic events up to
12months after coronary stenting, and that PRU≥240was a signiﬁcant
and independent predictor of ischemic events. Cuisset et al. [19] report-
ed that HPR on clopidogrel was a marker for increased periprocedural
myocardial infarction risk in patients with non-ST-elevationmyocardial
infarction. Parodi et al. [20] reported that the incidence of the primary
endpoint at 2 years was higher in ACS patients with HPR (14.6% vs
8.7%, p = 0.003). Our post-hoc analysis also showed an association be-
tween PRU at 5–12 h after the LD andMACE occurring up to 3 days after
PCI in ACS patients. By contrast, three recent randomized trials failed to
demonstrate the utility of the point of care approach in mainly stable
coronary artery disease patients with HPR treated with clopidogrel
[16,17,21]. The largest study, ADAPT-DES (Assessment of Dual Anti-
Platelet Therapy with Drug-Eluting Stents) [10], noted that a PRU
N208 was independently associated with the risk of stent thrombosis
within 30 days after PCI with drug-eluting stents in ACS patients (ad-
justed HR 3.91, p = 0.005), whereas no association was found in non-
ACS patients (adjustedHR 1.49, p= 0.59). These inconsistent outcomesFig. 4. Cumulative incidence ofmajor adverse cardiovascular events from baseline through to 24
The inset shows the cumulative incidence from baseline through to day 3. CI: conﬁdence intervamight be partly explained by enrollment of low-risk patients, and the
studies were probably underpowered to detect signiﬁcant associations
of PRU with MACE in a stable population.4.2. VerifyNow® cutoff value
To date, very few studies have examined the association between
platelet reactivity and MACE in prasugrel-treated patients, or identiﬁed
possible cutoff values for platelet reactivity as a predictor of MACE. In
this study, we focused on the fact that the risk of adverse events, includ-
ing occlusive and bleeding events, is greatest in the acute phase after PCI
and decreases thereafter in ACS patients treated with either drug. In
PRASFIT-ACS, most of the MACEs occurred within 3 days of PCI. There-
fore, we examined the association between platelet activity and the in-
cidence of MACE in the acute period after the LD in this post-hoc
analysis. We have demonstrated that the PRU at 5–12 h after the LD of
ADP receptor antagonists is a clinically meaningful parameter in terms
of the risk and beneﬁts of antiplatelet drugs in Japanese ACS patients.weeks according to platelet reactivity units≤262 or N262 at 5–12 h after the loading dose.
l;MACE:major adverse cardiovascular events; OR: odds ratio; PRU: platelet reactivity unit.
Table 3
Results of Cox multivariable regression analysis.
Variable Adjusted HR 95% CI p value
PRU (N262 vs. ≤262) 2.02 1.05–3.90 b0.05
Treatment with clopidogrel (vs. prasugrel) 1.10 0.57–2.12 0.77
Multivessel disease (vs. no) 1.97 1.13–3.43 b0.05
Hypertension 1.33 0.66–2.66 0.43
Dyslipidemia 1.36 0.66–2.80 0.41
Current smoker (vs. no) 0.85 0.49–1.54 0.58
Prior MI (yes vs. no) 1.96 0.77–4.96 0.16
HR: hazard ratio; CI: conﬁdence interval; PRU: platelet reactivity unit; MI: myocardial
infarction.
Fig. 5. Proportions of patients with platelet reactivity units N262. PRU: platelet reactivity unit.
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present study.
These ﬁndings are supported by the results of multivariate Cox re-
gression analysis and indicate that PRU should be maintained at 262
to prevent MACE within 3 days after PCI. Because prasugrel at a LD/
MD of 20 mg/3.75 mg achieved a signiﬁcantly higher response rate in
terms of PRU ≤262 than standard doses of clopidogrel and was associ-
ated with a lower incidence of MACE, this adjusted-dose prasugrel reg-
imen should achieve a lower incidence of ischemic events in Japanese
patients undergoing planned PCI for ACS. In prior studies involving
Western patients, the optimal PRU cutoff values were 240 [15,22], 235
[23], and 208 [10,16]. In our study of Japanese patients, the optimal cut-
off valuewas 262. In Korean patientswith/without acutemyocardial in-
farction undergoing PCI, the prevalence of ischemic events over 1 year
was signiﬁcantly higher in patients with a PRU ≥272 at 12–24 h after
PCI than in patients with a PRU b272 [24]. For example, the mean PRU
at baseline in patients with ACS in the TRILOGY (Targeted Platelet Inhi-
bition to Clarify the Optimal Strategy to Medically Manage Acute Coro-
nary Syndromes) sub-study [25] was between 200 and 250 in patients
aged b75 years and weighing ≥60 kg, although 95% of patients in that
study received clopidogrel before randomization, which probably re-
duced the PRU value at the baseline measurement. In the GRAVITAS
study [16], the median PRU was about 282 among patients with high
on-treatment residual platelet reactivity and 151 in patients with low
on-treatment platelet reactivity, but most patients received clopidogrel
before randomization to the study drug. In the present study, the mean
PRU at baselinewas 324.5± 59.0 and 325.3± 64.4 in the prasugrel and
clopidogrel groups, respectively. Considering these ﬁndings, it is possi-
ble that greater reductions in PRU from baseline, rather than achieving
a target PRU, may be associated with a reduced risk of MACE. These dif-
ferences in values also highlight the difﬁculty of directly comparing cut-
off values and baseline PRU values among studies because of differences
in study characteristics, including the time atwhich PRUwasmeasured,
treatment with an antiplatelet drug before the ‘baseline’ PRU measure-
ment, duration of follow-up, and the clinical settings/patients. In fact, in
one study that performed a bootstrap analysis of 10,000 replicates, the
predicted cutoff was 235 and the 95% CI was 174–291 PRU [23]. Like-
wise, in a collaborative meta-analysis of six studies, the optimal cutoff
for a composite of death,MI, or stent thrombosiswas 230 [26]. Thus, dif-
ferences in cutoff values among studies may be entirely reasonable
owing to study features, or there may be clinical implications for the re-
sults. Another factor that should be considered is the difference in PRU
measured before starting treatment.
4.3. CYP2C19 phenotype
Clopidogrel may not achieve optimal inhibition of platelet reactivity
in some patients, a phenomenon that is largely attributed to the pres-
ence of reduced-function CYP2C19 alleles [6,27,28]. In the presentstudy, the LD of clopidogrel did not reduce PRU for up to 12 h and the
proportion of patients in the clopidogrel group with PRU ≤262 was
smaller among patients with reduced-function alleles than among pa-
tients with normal function alleles. By contrast, the efﬁcacy of prasugrel
was hardly affected by reduced-function CYP2C19 alleles, and these fa-
vorable properties of prasugrel can be attributed to its rapid and potent
P2Y12 inhibitory effects.4.4. Limitations
We need to mention several important limitations. First, this was a
post-hoc analysis thatwas performed to investigate the relationship be-
tween platelet-reactivity and MACE. Therefore, a large prospective
study is needed to conﬁrm the clinical relevance of the PRU cutoff
value determined here. Second, the ACS patients included in this study
may not represent the types of patients treated in real-world settings.
Thus, the utility of PRU may be not identical in clinical practice. The LD
and MD of prasugrel used in the present study were about 1/3 of the
doses approved in Western countries. Therefore, it may be difﬁcult to
translate the present results to clinical practice in Western countries.
Nevertheless, clopidogrel was used at standard doses. It is also notable
that the HR for the incidence of MACEwas similar to that in each region
of TRITON-TIMI 38 [11]. Thus, we believe that PRU ≤262 is a clinically
relevant cutoff value for preventing MACE during the acute phase
after PCI in Japanese patients.Wemust also consider that the predictive
value of the obtained cutoff valuemight be low because of the relatively
small area under the curve (0.58). Finally, some genetic analyses have
shown that CYP2C19 polymorphisms are more frequent in Asian popu-
lations than in Western populations [29]. Thus, we cannot exclude the
possibility that ethnic factors may contribute to the differences in the
PRU cutoff values. Accordingly, further studies should assess the possi-
ble effects of ethnicity on PRU cutoff values.
Fig. 6. Proportion of patients with platelet reactivity units ≤262 at 5–12 h after the loading dose. The signiﬁcance of differences was tested using the χ2 test. PRU: platelet reactivity unit.
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We found that PRU ≤262 at 5–12 h after the LD was a clinically rel-
evant cutoff value for preventingMACEduring the acute, periprocedural
period (up to 3 days) after PCI. The proportion of non-responders
(i.e., PRU N262) was signiﬁcantly lower in the prasugrel group with a
dose adjusted for Japanese ACS patients (LD/MD: 20 mg/3.75 mg)
than in the clopidogrel group treated with a standard dose (300 mg/
75 mg). This difference was apparent in patients with normal or
reduced-function CYP2C19 polymorphisms.
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